8 reports

  • provides an overview of Seikagaku's key marketed viscosupplementation products.

In addition to marketed HA products, Seikagaku is also currently developing a next generation viscosupplementation treatment that incorporates the pain relief of NSAID drugs.

  • Orthobiologics
  • Anika Therapeutics, Inc.
  • Ferring International Center S.A.
  • Sanofi S.A.
  • Seikagaku Corporation
  • 7.5.3 Competitive Positioning
  • provides an overview of Seikagaku's key marketed viscosupplementation products.

Imposed austerity measures are expected to limit the number of elective surgical procedures, including knee replacement, over the next decade, causing physicians and patients to seek other methods of OA management and pain relief.

  • Orthobiologics
  • North America
  • Anika Therapeutics, Inc.
  • Sanofi S.A.
  • Seikagaku Corporation
  • provides an overview of Seikagaku's key pipeline viscosupplementation product.
  • provides an overview of Seikagaku's key marketed viscosupplementation products.

In addition to marketed HA products, Seikagaku is also currently developing a next generation viscosupplementation treatment that incorporates the pain relief of NSAID drugs.

  • Orthobiologics
  • Forecast
  • Ferring International Center S.A.
  • Sanofi S.A.
  • Seikagaku Corporation

PATIENTS EXPERIENCE PAIN RELIEF AND INCREASED MOBILITY FOR UP TO SIX MONTHS.

  • Orthobiologics
  • United States
  • Arthrex, Inc.
  • Biomet, Inc.
  • Smith & Nephew Plc

THE DATA DEMONSTRATED THAT CINGAL PROVIDED IMPROVED IMMEDIATE AND SHORT TERM PAIN RELIEF AFTER INJECTION AS COMPARED TO HA ALONE, AND ENHANCED RELIEF FROM OA-RELATED PAIN, STIFFNESS AND FUNCTION THROUGH ## WEEKS AS COMPARED TO SALINE.

  • Medical Device
  • Orthobiologics
  • Orthopedics
  • North America
  • Market Size

The data demonstrated that CINGAL provided improved immediate and short term pain relief after injection as compared to HA alone, and enhanced relief from OA-related pain, stiffness and function through ## weeks as compared to saline.

  • Orthobiologics
  • United States
  • Company
  • Company Financials
  • Market Size

The data demonstrated that CINGAL provided improved immediate and short term pain relief after injection as compared to HA alone, and enhanced relief from OA-related pain, stiffness and function through ## weeks as compared to saline.

  • Biomaterial Application
  • Clinical Trial
  • Medical Device
  • Orthobiologics
  • GlobalData's company

The data demonstrated that CINGAL provided improved immediate and short term pain relief after injection as compared to HA alone, and enhanced relief from OA-related pain, stiffness and function through ## weeks as compared to saline.

  • Clinical Trial
  • Institutional Construction
  • Orthobiologics
  • Pharmaceutical
  • Therapy